Tenecteplase for Stroke Patients Taking Blood Thinners
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether a clot-busting drug called tenecteplase works safely in people having a stroke who are already taking certain blood-thinning medications (like apixaban or rivaroxaban). The goal is to see if it can restore blood flow to the brain better than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and having a stroke with noticeable weakness or disability
- You arrived at the hospital within 4.5 hours of when your stroke started
- You are currently taking one of these blood thinners: dabigatran, apixaban, rivaroxaban, or edoxaban, and took your last dose within 48 hours
- You have not had a bleeding stroke (intracerebral hemorrhage) before
- Your kidneys are working reasonably well (eGFR above 30)
- You are not pregnant and have no serious infections like endocarditis or aortic tears
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the clot-busting drug tenecteplase is safe and effective for people having an ischemic stroke who have recently taken blood thinners (DOACs). If you qualify, you may receive either tenecteplase or a placebo within 24 hours of your last known well time.
This trial tests a new medication called rhTNK-tPA for treating acute ischemic stroke (a clot in the brain) up to 24 hours after symptom onset. The study uses simplified imaging to determine eligibility and aims to help patients recover better outcomes.
This trial tests a clot-busting drug called tenecteplase, given directly into the blocked artery, for people who have had a stroke caused by a medium-sized brain vessel blockage within the last 24 hours. It aims to see if this treatment is safe and effective in improving recovery.
This trial tests if a clot-busting drug called tenecteplase can improve outcomes for people with a large vessel stroke when treatment starts 4.5 to 24 hours after symptoms began, and when a mechanical clot removal procedure (EVT) is not available. You would receive tenecteplase or standard medical care to see which works better.
This study tests a clot-dissolving drug called tenecteplase given directly into the artery after a mechanical thrombectomy (clot removal). The goal is to see if it helps improve blood flow to the small vessels in the brain after the main clot is removed.
This trial tests whether giving a clot-dissolving medicine (alteplase or tenecteplase) is safe and effective for people who have had a stroke and are taking a blood thinner (DOAC) like apixaban or rivaroxaban. It aims to see if this treatment can still be given within a few hours of the stroke.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.